WuXi Biologics (2269.HK), the world’s leading open biopharmaceutical technology platform company, today announced that it has formally signed a cooperation framework agreement with Anke Bio (300009.SZ) for the development of an anti-tumor bispecific antibody. Achieve cooperation.
According to the agreement, Anke Bio will develop a new generation of tumor immunotherapy with innovative bispecific antibody layout based on WuXiBodyTM, a double-antibody platform with its own intellectual property rights. Through strong alliances, the two sides make full use of their respective advantages and resources to cooperate in research and development and other aspects to achieve win-win cooperation in the field of biomedical research and development.
About WuXiBodyTM
WuXiBodyTM is a bispecific antibody technology platform with independent intellectual property rights and is expected to be one of the best bispecific antibody platforms in the industry. The platform breaks through the bottleneck of most bispecific antibody platform technology, effectively overcomes the challenges of low expression, high polymer and low purification yield during bispecific antibody development, saving 6 to 18 months per project. The bispecific antibody has been developed to a maximum of 16 g/L, and the purity and yield are over 95% after one step of Protein A purification. At the same time, the WuXiBodyTM platform combines unique flexibility to construct a variety of valences (such as bivalent, trivalent or tetravalent bispecific antibodies) and structures to meet the biological properties of different projects.
About Anke Bio
Anke Bio has been committed to the research, development, production and sales of biomedicine. The company attaches great importance to R&D and innovation, implements the innovation-driven strategy in depth, and has a solid foundation for technology development and industrialization. At present, Anke Bio has nearly ten research and development of monoclonal antibody projects, and is in a leading position in the research and development of antibody drugs.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the world’s leading open, integrated biopharmaceutical capability and technology enabling platform. As of June 30, 2018, there were 187 comprehensive projects developed on the WuXi Biologics Platform, including 98 in the preclinical research phase, 78 in the early clinical phase (Phase I, Phase II), and 10 in the later clinical phase. (III) and 1 in the commercial production stage. It is estimated that by 2021, the company’s planned biopharmaceutical production bases in China, Ireland, Singapore, and the United States will have a combined capacity of approximately 220,000 liters, which will ensure that the company provides customers with biopharmaceuticals that meet global quality standards through a robust global supply chain network. For more information, please visit www.wuxibiologics.com.cn.